by Eric Christianson | Feb 19, 2025 | Cardiovascular Medication and Disease State Clinical Pearls
Diltiazem and verapamil are two non-dihydropyridine calcium channel blockers (non-DHP CCBs) most commonly used in managing certain cardiac conditions. Even though they fall into the same medication class, these medications have important pharmacological differences...
by Eric Christianson | Feb 16, 2025 | Renal, Urology, and Electrolytes Medication and Disease State Clinical Pearls
It can be overwhelming walking into the pharmacy and looking down the vitamin aisle – especially when you finally find a specific supplement, only to discover there are numerous forms lining the shelves. This gets even more challenging when you don’t know which salt...
by Eric Christianson | Feb 12, 2025 | Cardiovascular Medication and Disease State Clinical Pearls
This video is part of a three-part series covering new literature that could influenceclinical practice. In this video, I discuss the combined usage of antiplatelets with DOACsin patients with ASCVD risk and atrial fibrillation. Each mechanism of action is reviewed,as...
by Eric Christianson | Feb 9, 2025 | Cardiovascular Medication and Disease State Clinical Pearls
This video is part of a three-part series covering new literature that could influence clinical practice. In this video, I discuss whether beta-blocker use post-MI is beneficial for patients with HFpEF. Background about the mechanism of action and typical place in...
by Eric Christianson | Feb 5, 2025 | Cardiovascular Medication and Disease State Clinical Pearls
This video is part of a three-part series covering new literature that could influence clinical practice. Finerenone has been studied in the setting of HFpEF and I review this topic. More specifically, in this video, I discuss the background of why finerenone may be...
